AcuCort AB (ACUC.ST)

SEK 0.74

(-1.73%)

EBITDA Summary of AcuCort AB

  • AcuCort AB's latest annual EBITDA in 2023 was -13.69 Million SEK , up 12.25% from previous year.
  • AcuCort AB's latest quarterly EBITDA in 2024 Q2 was -3.78 Million SEK , down -6.4% from previous quarter.
  • AcuCort AB reported an annual EBITDA of -14.77 Million SEK in 2022, down -30.79% from previous year.
  • AcuCort AB reported an annual EBITDA of -11.32 Million SEK in 2021, down -45.76% from previous year.
  • AcuCort AB reported a quarterly EBITDA of -3.78 Million SEK for 2024 Q2, down -6.4% from previous quarter.
  • AcuCort AB reported a quarterly EBITDA of -3.68 Million SEK for 2023 Q4, down -21.3% from previous quarter.

Annual EBITDA Chart of AcuCort AB (2023 - 2016)

Historical Annual EBITDA of AcuCort AB (2023 - 2016)

Year EBITDA EBITDA Growth
2023 -13.69 Million SEK 12.25%
2022 -14.77 Million SEK -30.79%
2021 -11.32 Million SEK -45.76%
2020 -7.76 Million SEK 7.43%
2019 -8.36 Million SEK -34.54%
2018 -6.22 Million SEK -33.26%
2017 -4.66 Million SEK -143.2%
2016 -1.91 Million SEK 0.0%

Peer EBITDA Comparison of AcuCort AB

Name EBITDA EBITDA Difference
AlzeCure Pharma AB (publ) -37.86 Million SEK 63.845%
BioGaia AB (publ) 466.19 Million SEK 102.937%
Enzymatica AB (publ) -41.12 Million SEK 66.706%
Enorama Pharma AB (publ) -43.05 Million SEK 68.2%
Gabather AB (publ) 37 Thousand SEK 37102.703%
Klaria Pharma Holding AB (publ.) -14.77 Million SEK 7.305%
Moberg Pharma AB (publ) -26.95 Million SEK 49.216%
Nanexa AB (publ) -70.79 Million SEK 80.66%
Newbury Pharmaceuticals AB (publ) -12.34 Million SEK -10.948%
ODI Pharma AB 1.36 Million SEK 1101.27%
Orexo AB (publ) -22 Million SEK 37.768%
Probi AB (publ) 115.61 Million SEK 111.842%
Swedencare AB (publ) 484 Million SEK 102.829%
Swedish Orphan Biovitrum AB (publ) 7.23 Billion SEK 100.189%
Toleranzia AB -7.39 Million SEK -85.064%
Vivesto AB -89.75 Million SEK 84.747%